Di-n-butyltin aminoarylcarboxylates: Structure, properties and in vitro antitumor activity

Applied Organometallic Chemistry

Volumn 16, Issue 10, 2002, Pages 587-592

  Pruchnik, Florian P ^a   Bańbuła, Małgorzata ^a   Ciunik, Zbigniew ^a   Chojnacki, Henryk ^b   Latocha, Małgorzata ^c   Skop, Barbara ^c   Wilczok, Tadeusz ^c  

^a UNIVERSITY OF WROC AW   (Poland)

^b WROCLAW UNIVERSITY OF TECHNOLOGY   (Poland)

^c MEDICAL UNIVERSITY OF SILESIA   (Poland)

Author keywords

Antitumor agents; Crystal structure; Organotin complexes

Indexed keywords

CARBOXYLIC ACID DERIVATIVE; DI N BUTYLTIN 2 [4 (DIMETHYLAMINO)PHENYLAZO]BENZOATE; DI N BUTYLTIN 3,4 DIAMINOBENZOATE; DI N BUTYLTIN 3,5 DIAMINOBENZOATE; DIBUTYLTIN; LIGAND; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CHEMICAL BOND; COMPLEX FORMATION; CONTROLLED STUDY; CYTOTOXICITY; DRUG ACTIVITY; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; HUMAN CELL; IN VITRO STUDY; INFRARED SPECTROSCOPY; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; STRUCTURE ACTIVITY RELATION; X RAY ANALYSIS; X RAY CRYSTALLOGRAPHY;

EID: 0036784337     PISSN: 02682605     EISSN: None     Source Type: Journal    
DOI: 10.1002/aoc.347     Document Type: Article

References (26)

1. Wong E and Giandomenico CM. Chem. Rev. 1999; 99: 2451.
2. Clarke MJ, Zhu F and Frasca DR. Chem. Rev. 1999; 99: 2511.
3. Huber F and Barbieri R. In Metal Complexes in Cancer Chemotherapy, Keppler B (ed.). VCH: Weinheim, New York, 1993; 351.
4. Crowe AJ. In Metal Complexes in Cancer Chemotherapy, Keppler B (ed.). VCH: Weinheim, New York, 1993; 369.
5. Gielen M. Coord. Chem. Rev. 1966; 151: 41.
6. Gielen M, Biesemans M, de Vos D and Willem R. J. Inorg. Biochem. 2000; 79: 139, and references cited therein.
7. Willem R, Bouhdid A, Mahieu B, Ghys L, Biesemans M, Tieking ERT, de Vos D and Gielen M. J. Organomet. Chem. 1997; 531: 151.
8. Gielen M, Bouhdid A, Kayser F, Biesemans M, de Vos D, Mahieu B and Willem R. Appl. Organomet. Chem. 1995; 9: 251.
9. Tao J, Xiao W and Yang Q. J. Organomet. Chem. 1997; 531: 223.
10. Bonire JJ and Fricker SP. J. Inorg. Biochem. 2001; 83: 217.
11. De Vos D, Willem R, Gielen M, van Wingerden KE and Nooter K. Met. Based Drugs 1998; 5: 179.
12. Kemmer M, Gielen M, Biesemans M, de Vos D and Willem R. Met. Based Drugs 1998; 5: 189.
13. Boo PA, Casas JS, Castellano EE, Couce MD, Freijanes E, Furlani A, Russo U, Scarcia V, Sordo J and Varela M. Appl. Organomet. Chem. 2001; 15: 75.
14. Li J, Ma Y, Liu R and Li J. Appl. Organomet. Chem. 2001; 15: 227.
15. Tiekink ERT, Gielen M, Bouhdid A, Willem R, Bregadze VI, Ermanson LV and Glazun SA. Met. Based Drugs 1997; 4: 75.
16. Gielen M, Handlir K, Hollein M and de Vos D. Met. Based Drugs 2000; 7: 233.
17. Sheldrick GM. SHELXS97, program for solution of crystal structures. University of Göttingen, 1997.
18. Sheldrick GM. SHELXL97, program for crystal structure refinement. University of Göttingen, 1997.
19. MOPAC2000, Version 1.06, Fujitsu Limited, 1999.
20. Pruchnik FP and Duś D. J. Inorg. Biochem. 1996; 61: 55.
21. Pruchnik FP, Starosta R, Ciunik Z, Opolski A, Wietrzyk J, Wojdat E and Duś D. Can. J. Chem. 2001; 79: 868.
22. Tiekink ERT. Appl. Organomet. Chem. 1991; 5: 1.
23. Gielen M, Meunier-Piret J, Biesemans M, Willem R and El Khloufi A. Appl. Organomet. Chem. 1992; 6: 59.
24. Gimenez J, Michel A, Pétiaud R and Llauro M-F. J. Organomet. Chem. 1999; 575: 286.
25. Primel O, Llauro M-F, Pétiaud R and Michel A. J. Organomet. Chem. 1998; 558: 19.
26. Wrackmeyer B. Annu. Rep. NMR Spectrosc. 1999; 38: 203.